Ovarian cancer is falling in rich countries, rising in parts of Asia and Africa

A global review published in Cancer Biology & Medicine finds ovarian cancer rates are declining in high-income countries but increasing in some lower-resource regions. The study says prevention, genetic testing and risk-reducing surgery may matter more than screening for the general population.

Why it matters: - Ovarian cancer is still a major global killer of women, with more than 324,000 new cases and nearly 207,000 deaths estimated in 2022. - Five-year survival remains below 50% in most countries. - No screening strategy has been shown to reduce mortality in average-risk women. - The disease is rising in parts of Asia and Africa even as rates fall in several wealthy nations.

What happened: - Researchers from the National Cancer Center of China and Yale University published a comprehensive review in Cancer Biology & Medicine in 2026. - The review synthesized data from GLOBOCAN, the Global Burden of Disease Study, CONCORD-3 and more than 50 meta-analyses and large population-based studies. - The paper mapped incidence, mortality, disability-adjusted life years and modifiable risk factors across regions and populations.

The details: - From 1990 to 2021, the age-standardized incidence rate fell from 7.22 to 6.71 per 100,000. - Mortality fell from 4.73 to 4.06 per 100,000 over the same period. - Eastern Europe had the highest incidence at 11.0 per 100,000. - Middle Africa had the lowest incidence at 4.3 per 100,000. - High-income countries including the United States, Austria and Norway showed declining incidence. - Parts of Asia and Africa showed increasing rates. - Survival has improved modestly in some countries but remains below 20% in India. - Each additional birth reduces risk by about 6%. - Every 12 months of breastfeeding lowers risk by roughly 10%. - Pro-inflammatory diets, measured by the Dietary Inflammatory Index, increase risk by 42%. - Obesity is linked to serous borderline, endometrioid and mucinous subtypes. - Prolonged sitting for 10 or more hours per week raises risk by 25% to 40%. - Ever-use of oral contraceptives is associated with about a 27% risk reduction. - Menopausal hormone therapy increases risk, especially for serous and endometrioid cancers. - For BRCA1 or BRCA2 carriers, risk-reducing salpingo-oophorectomy cuts risk by 80% to 97%. - Black patients had 25% lower treatment adherence and 18% higher mortality than white patients, highlighting access and socioeconomic gaps. - The authors said ovarian cancer behaves differently across regions, populations and histologic subtypes. - The authors also said prevention is achievable through tailored strategies, including breastfeeding, physical activity, obesity and diabetes management, and access to genetic testing and preventive surgery. - The full report is available at the study DOI.

Between the lines: - The global averages mask a split reality: some countries are improving, while others are moving in the wrong direction. - The findings point to prevention as the main near-term lever, since broad screening has not delivered a mortality benefit in average-risk women. - The disparity in outcomes suggests that healthcare access may be as important as biology in determining survival. - Emerging tools such as AI-enabled screening, DNA methylation markers and circulating tumor DNA may help, but the review says prospective trials are still needed.

What's next: - Public health programs are likely to focus more on modifiable lifestyle factors and risk-reduction counseling. - Health systems may concentrate genetic testing and preventive surgery on women at highest inherited risk. - Researchers still need large prospective studies before new biomarker-based or AI screening tools can be used routinely. - Ovarian cancer cases are projected to increase by nearly 47% by 2050, raising the urgency for prevention efforts.

The bottom line: - Ovarian cancer prevention is likely to save more lives than population-wide screening in the near term, especially if countries tailor interventions to local risk and access gaps.